SCHEMBL1098005

SCHEMBL1098005

CC(=O)Oc1c(Cl)cc(Cl)cc1C(=O)O

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AKR1C4 P17516 1/20 0.52
AKR1C3 P42330 1/20 0.52
AKR1C2 P52895 1/20 0.52
AKR1C1 Q04828 1/20 0.52
KDM4E B2RXH2 5/20 0.45
ALDH1A1 P00352 5/20 0.45
HSD17B10 Q99714 5/20 0.45
HPGD P15428 4/20 0.45
MAPK1 P28482 1/20 0.45
CASP1 P29466 2/20 0.44
TSHR P16473 2/20 0.44
TP53 P04637 1/20 0.44
SMN1; SMN2 Q16637 1/20 0.44
TDP1 Q9NUW8 2/20 0.44
MEN1 O00255 1/20 0.44
RAB9A P51151 1/20 0.44
KMT2A Q03164 1/20 0.44
NPSR1 Q6W5P4 1/20 0.44
CFD P00746 1/20 0.42
CYP3A4 P08684 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL1097098 0.98 AKR1C4 (0.50) AKR1C4AKR1C3AKR1C2AKR1C1KDM4E
SCHEMBL1097096 0.86 ABCB11 (0.41) AKR1C4AKR1C3AKR1C2AKR1C1KDM4E
SCHEMBL14339912 0.85 AKR1C4 (0.47) AKR1C4AKR1C3AKR1C2AKR1C1KDM4E
SCHEMBL4645395 0.85 ABCB11 (0.49) KDM4EALDH1A1HSD17B10TSHRTP53
SCHEMBL18871612 0.83 ABCB11 (0.45) AKR1C4AKR1C3AKR1C2AKR1C1KDM4E
SCHEMBL1096935 0.83 HPGD (0.45) AKR1C4AKR1C3AKR1C2AKR1C1KDM4E
SCHEMBL1096938 0.82 KDM4E (0.45) AKR1C4AKR1C3AKR1C2AKR1C1KDM4E
Hydrochloric Acid SCHEMBL1098712 0.82 HPGD (0.44) AKR1C4AKR1C3AKR1C2AKR1C1KDM4E
SCHEMBL30084374 0.81 ACLY (0.56) AKR1C4AKR1C3AKR1C2AKR1C1KDM4E
SCHEMBL423692 0.81 ACLY (0.56) AKR1C4AKR1C3AKR1C2AKR1C1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-105218393-A The method of synthesis mycotoxin absorbant and preparation and the described synthesis mycotoxin absorbant of use ALLTECH INC 2016-01-06 CN claimed
EP-2470894-B1 SYNTHETIC MYCOTOXIN ADSORBENTS AND METHODS OF MAKING AND UTILIZING THE SAME ALLTECH INC (US) 2021-12-29 EP disclosed
EP-2470894-B1 SYNTHETIC MYCOTOXIN ADSORBENTS AND METHODS OF MAKING AND UTILIZING THE SAME ALLTECH INC (US) 2021-12-29 EP disclosed
CN-102549424-B Synthetic mycotoxin adsorbents and methods of making and using the same ALLTECH, INC. (US) 2016-01-13 CN disclosed
CN-105218393-A The method of synthesis mycotoxin absorbant and preparation and the described synthesis mycotoxin absorbant of use ALLTECH INC 2016-01-06 CN disclosed
CN-104190378-A SYNTHETIC MYCOTOXIN ADSORBENTS AND METHODS OF MAKING AND UTILIZING THE SAME ALLTECH INC 2014-12-10 CN disclosed
US-RE45274-E1 Synthetic mycotoxin adsorbents and methods of making and utilizing the same ALLTECH, INC. (US) 2014-12-02 US disclosed
US-8426541-B2 Synthetic mycotoxin adsorbents and methods of making and utilizing the same ALLTECH, INC. (US) 2013-04-23 US disclosed
US-8426541-B2 Synthetic mycotoxin adsorbents and methods of making and utilizing the same ALLTECH, INC. (US) 2013-04-23 US disclosed
US-8324405-B2 Chromene derivatives and use thereof as HIF hydroxylase activity inhibitors FIBROGEN, INC. (US) 2012-12-04 US disclosed
US-20120214897-A1 SYNTHETIC MYCOTOXIN ADSORBENTS AND METHODS OF MAKING AND UTILIZING THE SAME ALLTECH, INC. (US) 2012-08-23 US disclosed
US-20120214897-A1 SYNTHETIC MYCOTOXIN ADSORBENTS AND METHODS OF MAKING AND UTILIZING THE SAME ALLTECH, INC. (US) 2012-08-23 US disclosed
EP-2470894-A1 SYNTHETIC MYCOTOXIN ADSORBENTS AND METHODS OF MAKING AND UTILIZING THE SAME Alltech, Inc. (US) 2012-07-04 EP disclosed
CN-102549424-A Synthetic mycotoxin adsorbents and methods of making and using the same ALLTECH INC 2012-07-04 CN disclosed
US-8153737-B2 Synthetic mycotoxin adsorbents and methods of making and utilizing the same ALLTECH, INC. (US) 2012-04-10 US disclosed
WO-2011031562-A1 SYNTHETIC MYCOTOXIN ADSORBENTS AND METHODS OF MAKING AND UTILIZING THE SAME ALLTECH, INC. (US) 2011-03-17 WO disclosed
US-20110054132-A1 SYNTHETIC MYCOTOXIN ADSORBENTS AND METHODS OF MAKING AND UTILIZING THE SAME ALLTECH, INC. (US) 2011-03-03 US disclosed
US-20110054132-A1 SYNTHETIC MYCOTOXIN ADSORBENTS AND METHODS OF MAKING AND UTILIZING THE SAME ALLTECH, INC. (US) 2011-03-03 US disclosed
US-20100331400-A1 CHROMENE DERIVATIVES AND USE THEREOF AS HIF HYDROXYLASE ACTIVITY INHIBITORS FIBROGEN, INC. 2010-12-30 US disclosed
WO-2009100250-A1 CHROMENE DERIVATIVES AND USE THEREOF AS HIF HYDROXYLASE ACTIVITY INHIBITORS FIBROGEN, INC. (US) 2009-08-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100331400-A1 CHROMENE DERIVATIVES AND USE THEREOF AS HIF HYDROXYLASE ACTIVITY INHIBITORS HIF1AN, HIF1A, EGLN2 AKR1C4 531/4885AKR1C3 330/4885AKR1C2 253/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.